HIGHLIGHTS
- who: Adrien Joseph and colleagues from the , Paris, France have published the article: Acute Kidney Injury in Cancer Immunotherapy Recipients, in the Journal: Cells 2022, 11, 3991. of /2022/
- what: Cancer immunotherapy has reshaped cancer therapy and led to the description of new toxicities, including renal toxicities.
- future: CD19 is currently the most widely used target (Blinatumomab) but bispecific antibodies redirecting T_cells against CD20 (Mosunetuzumab) have recently been approved for follicular lymphoma and new antibodies targeting BCMA for multiple myeloma are likely to enter clinical practice in the near future .
SUMMARY . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.